ESTRO 2024 - Abstract Book

S2196

Clinical - Upper GI

ESTRO 2024

Considering the volumetric assessment of response, the median relative volume percentage of the treated lesions (interquartile range) was 43%(25-70%) at 1 month, 26% (0-47%) at 2 months,13% (0-48%) at 3 months, 0% (0-28%) at 4 months, 0% (0-4%) at 5 months and 0% (0-0%) at 6 months, with some outliers, took a longer time to achieve the best response, with certain cases requiring up to 36 months (figure 1).

Characteristics

Number of evaluable patients

49

Number of evaluable lesions Volume of lesions (range)

62 8.15 (0.5-539) cm 3

Median age (range)

74 (53-93)

Gender:

17 35

Female Male

Median prescribed physical dose Medina dose as EQD2 α/ β 10 (range) Gy

40 (24-66) Gy 60 (32-87.5) Gy

Median number of fractions (range)

5 (3-12) Fraction

Table- 1: patients’ characteristics

Conclusion:

Our study highlights the response of HCC following SBRT necessities for longer observation periods. Furthermore, our findings underscore the enhanced sensitivity of volumetric lesion assessment compared to traditional two dimensional assessment methods for residual enhancement in discerning treatment response after SBRT, emphasizing the importance of adopting a comprehensive approach to evaluate and monitor the efficacy of SBRT in HCC.

Keywords: HCC, SBRT, Response assessment

References:

1. Voizard N, Cerny M, Assad A, Billiard JS, Olivié D, Perreault P, Kielar A, Do RKG, Yokoo T, Sirlin CB, et al. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging [Internet]. 2019 Dec 1;10(1):1 – 22. Available from: https://insightsimaging.springeropen.com/articles/10.1186/s13244-019-0801-z

2.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma.; Available

from: http://dx.doi.org/10.1055/s-0030-1247132.